Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) insider Jason B. Shandell sold 26,335 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, November 28th. The stock was sold at an average price of $20.48, for a total value of $539,340.80. Following the transaction, the insider now owns 205,004 shares of the company’s stock, valued at $4,198,481.92. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) traded down 0.10% during trading on Tuesday, reaching $20.33. The company’s stock had a trading volume of 213,088 shares. The stock has a market cap of $935.65 million, a P/E ratio of 44.39 and a beta of 1.86. The stock has a 50-day moving average of $19.15 and a 200-day moving average of $17.78. Amphastar Pharmaceuticals Inc. has a 52-week low of $10.50 and a 52-week high of $21.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Tuesday, November 8th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.03 by $0.11. The firm earned $64.20 million during the quarter, compared to the consensus estimate of $65.12 million. Amphastar Pharmaceuticals had a return on equity of 6.79% and a net margin of 7.75%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.01) earnings per share. Analysts predict that Amphastar Pharmaceuticals Inc. will post $0.47 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

COPYRIGHT VIOLATION WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/29/insider-selling-amphastar-pharmaceuticals-inc-amph-insider-sells-26335-shares-of-stock.html.

Several research analysts have recently commented on AMPH shares. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Monday, August 1st. Needham & Company LLC lifted their target price on Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Jefferies Group set a $21.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $23.00 target price (up from $22.00) on shares of Amphastar Pharmaceuticals in a research note on Wednesday, September 7th. Finally, BMO Capital Markets reissued a “hold” rating and set a $17.00 price target on shares of Amphastar Pharmaceuticals in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Amphastar Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $20.17.

Several hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $1,521,000. EAM Investors LLC acquired a new position in Amphastar Pharmaceuticals during the second quarter valued at about $3,978,000. DekaBank Deutsche Girozentrale raised its position in Amphastar Pharmaceuticals by 25.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 24,600 shares of the company’s stock valued at $396,000 after buying an additional 5,000 shares in the last quarter. Emerald Acquisition Ltd. acquired a new position in Amphastar Pharmaceuticals during the second quarter valued at about $3,227,000. Finally, Swiss National Bank raised its position in Amphastar Pharmaceuticals by 8.1% in the second quarter. Swiss National Bank now owns 58,800 shares of the company’s stock valued at $948,000 after buying an additional 4,400 shares in the last quarter. 48.22% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

5 Day Chart for NASDAQ:AMPH

Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.